2014
A germline mutation in the BRCA13’UTR predicts Stage IV breast cancer
Dorairaj JJ, Salzman DW, Wall D, Rounds T, Preskill C, Sullivan C, Lindner R, Curran C, Lezon-Geyda K, McVeigh T, Harris L, Newell J, Kerin MJ, Wood M, Miller N, Weidhaas JB. A germline mutation in the BRCA13’UTR predicts Stage IV breast cancer. BMC Cancer 2014, 14: 421. PMID: 24915755, PMCID: PMC4059881, DOI: 10.1186/1471-2407-14-421.Peer-Reviewed Original ResearchConceptsStage IV breast cancerBreast cancerTumor biologyCancer riskBRCA1 gene expressionTriple-negative breast cancerLess dense breastsStage IV diseaseAggressive tumor biologyBreast cancer patientsBreast cancer riskOvarian cancer riskCohort of womenNegative breast cancerTriple-negative samplesBreast cancer cell linesBreast tumor tissuesHigh-risk familiesNegative patient samplesCancer cell linesObese womenGene expressionCancer patientsTT variantBreast program
2012
Hypoxia-induced protein CAIX is associated with somatic loss of BRCA1 protein and pathway activity in triple negative breast cancer
Neumeister VM, Sullivan CA, Lindner R, Lezon-Geyda K, Li J, Zavada J, Martel M, Glazer PM, Tuck DP, Rimm DL, Harris L. Hypoxia-induced protein CAIX is associated with somatic loss of BRCA1 protein and pathway activity in triple negative breast cancer. Breast Cancer Research And Treatment 2012, 136: 67-75. PMID: 22976806, DOI: 10.1007/s10549-012-2232-0.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntigens, NeoplasmBiomarkers, TumorBRCA1 ProteinBreast NeoplasmsCarbonic Anhydrase IXCarbonic AnhydrasesCell HypoxiaFemaleGene Expression Regulation, NeoplasticHumansMiddle AgedMutationNeoplasm StagingReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneSignal TransductionConceptsTriple-negative breast cancerCA IX protein expressionNegative breast cancerBreast cancer cohortTNBC cohortProtein expressionBreast cancerCancer cohortCA IXTriple-negative patientsWorse overall survivalBreast cancer patientsTriple-negative phenotypePARP inhibitor therapyUnselected breast cancer cohortGene expression signaturesInhibitor therapyNegative patientsOverall survivalUnselected cohortCancer patientsBRCA1 protein expressionUseful biomarkerPatientsDefective homologous recombination
2009
Tissue Microarray Analysis of 560 Patients with Colorectal Adenocarcinoma: High Expression of HuR Predicts Poor Survival
Yoo PS, Sullivan CA, Kiang S, Gao W, Uchio EM, Chung GG, Cha CH. Tissue Microarray Analysis of 560 Patients with Colorectal Adenocarcinoma: High Expression of HuR Predicts Poor Survival. Annals Of Surgical Oncology 2009, 16: 200. PMID: 19009247, DOI: 10.1245/s10434-008-0209-3.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAntigens, SurfaceAutomationBiomarkers, TumorColorectal NeoplasmsELAV ProteinsELAV-Like Protein 1FemaleFollow-Up StudiesHumansImage Processing, Computer-AssistedImmunoenzyme TechniquesMaleMiddle AgedNeoplasm StagingPlatelet Endothelial Cell Adhesion Molecule-1PrognosisRNA-Binding ProteinsSurvival RateTissue Array AnalysisVascular Endothelial Growth Factor AYoung AdultConceptsVascular endothelial growth factorColorectal adenocarcinomaPoor survivalHuR expressionKaplan-Meier analysisNovel therapeutic targetTissue microarray analysisEndothelial growth factorChi-squared testInstitutional review boardHuR protein expressionAdvanced diseaseClinical outcomesHighest quartileIndependent predictorsPrognostic significanceColorectal cancerCox regressionTumor stageMetastasis stageColorectal carcinomaLowest quartileClinical dataExpression of HuRTissue microarray